How states are cracking down on rising prescription drug costs

Trudy Zimmerman, then 65, pulls out medications from her medicine cabinet at her home in Burlington, Washington, on March 5, 2023.

Trudy Zimmerman, then 65, pulls out medications from her medicine cabinet at her home in Burlington, Washington, on March 5, 2023. The Washington Post / Contributor via Getty Images

 

Connecting state and local government leaders

From creating drug price review boards to bulk purchasing medications, state officials are keen on keeping health care costs down amid skyrocketing prescription costs.

For many Americans, prescription drugs are too costly. Last year, 28% of U.S. adults struggled to afford their prescription medications. And from 2017 to 2022, state Medicaid spending on prescriptions saw a 47% increase.

The rapid rise of drug prices has been the impetus behind growing state efforts to develop boards or programs to reduce drug costs. Officials from three states where such endeavors are underway sat down last week for a webinar hosted by the Center for American Progress to discuss how they are approaching the task for their constituents. 

One strategy to rein in prescription costs is the development of state prescription drug affordability boards, which, as of January, have spread to 11 states. In 12 other states, legislation to create similar boards is pending, according to the law firm Morgan Lewis

Though different in scope across states, prescription review boards are generally responsible for determining if certain drugs are unaffordable to patients and/or health plan payers. Maryland’s board—the nation’s first after it was created in 2019—confirmed late last month that it will officially begin cost reviews on six medications. The selected treatments, which address conditions like diabetes, heart and kidney disease, plaque psoriasis, Crohn’s and eczema, could then be subject to payment limits if deemed unaffordable. 

The cost review process allows officials to determine “whether or not the drug has led or will lead to affordability challenges for the state health care system or higher out-of-pocket costs for patients,” said ​​Andrew York, executive director of the Maryland Prescription Drug Affordability Board. To assess affordability, board members will review public comments from patients and stakeholders and may request cost-related information from drug manufacturers, health maintenance organizations, managed care organizations, pharmacy benefit managers and other sources. 

York said they hope to complete the process in the fall. He also pointed to Colorado, which established its Prescription Drug Affordability Review Board in 2021, and has already finished the cost review process for the drug Stelara, which is used to treat conditions like arthritis and plaque psoriasis. An affordability report released in May from the board found Stelara costs patients an average of $5,875 in out-of-pocket costs annually. Based on those findings, the board decided last month that the prescription is unaffordable, which makes it eligible for payment limits. 

Meanwhile, New Jersey is taking a different approach with its benchmark reporting program, said Shabnam Salih, director of the state’s Office of Health Care Affordability and Transparency, which looks to reduce the rate of health care cost growth. 

Established in 2021 under an executive order, the Health Care Affordability, Responsibility and Transparency, or HART, program, establishes a target rate of growth for health care spending by the state from 2023 to 2027. The order was accompanied by a compact to ensure health care industry stakeholders also work towards reducing spending benchmarks, Salih said. 

The cost growth benchmarks decrease over time, starting at 3.5% annual growth over total health care expenditures in 2022 for 2023 and ending at a 2.8% growth over expenditures in 2026 for 2027. 

“[P]rescription drug cost growth continues to be a challenge nationwide and for New Jersey residents, families, and employers, including the State, and threaten to outpace the growth of the State’s economy and residents’ wages,” the order stated. “[T]he steadily increasing costs of health care and prescription drugs have limited access to quality health care for lower- and middle-income residents and elderly residents alike.” 

The program will leverage insurance claims data to assess spending growth based on factors like total medical expenditures for health care services, the net cost of private insurance for residents or the value of pharmacy manufacturer rebates for individuals. Plus, the program will release annual reports to help policymakers gauge how the state and stakeholders are meeting benchmark goals and identify cost drivers to inform cost reduction efforts. 

On the western side of the country, Nevada is tackling high prescription expenses through the ArrayRx Solutions program. Under the program, states can negotiate lower drug prices with manufacturers through bulk purchases of medications. The state entered the program in 2022, joining Oregon and Washington. Connecticut was the latest state to join last year. 

Individuals can also get state-backed prescription drug discount cards through ArrayRx, with no income, age or citizenship status requirements, said Beth Slamowitz, senior policy adviser on pharmacy at the Nevada Department of Health and Human Services. The card can help patients save up to 80% on generic prescriptions and 20% on name brand medications. 

More than 15,000 individuals in the state use the discount card, Slamowitz said, and the average saving for patients per prescription is $185 to $200. It’s particularly helpful for individuals who are uninsured or have high deductibles under their coverage plans. 

“Most importantly, I think, for Nevada, was that [ArrayRx] maintains sustainability for our pharmacies, because it doesn’t charge fees back to the pharmacy,” she said. Other discount cards, for instance, often incur additional fees when used by individuals, impact the pharmacy’s reimbursement rate. 

ArrayRx provides other programs for participating states, such as a voucher initiative that helps individuals fill their prescriptions at no cost to them and a pharmacy benefit manager oversight program.

“There is no one part of the supply chain, or there is no one part of the [health care] industry that is responsible” for increasing drug costs, Salih said, so it’s “really important for [states] to take a comprehensive and holistic approach.”

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.